Bio-Rad Laboratories (NYSE:BIO.B) Posts Quarterly Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B) announced its earnings results on Thursday. The company reported $2.51 EPS for the quarter, Zacks reports. Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.19%.

Bio-Rad Laboratories Stock Performance

Shares of BIO.B stock remained flat at $295.05 during trading on Thursday. The stock had a trading volume of 7 shares, compared to its average volume of 104. The company has a current ratio of 5.44, a quick ratio of 3.94 and a debt-to-equity ratio of 0.18. The company has a market cap of $7.96 billion, a P/E ratio of -12.14 and a beta of 1.01. The business’s 50 day moving average is $308.74 and its two-hundred day moving average is $289.38. Bio-Rad Laboratories has a 52 week low of $225.29 and a 52 week high of $343.85.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.